Skip to main content

Table 2 Culture conversion by culture method and treatment arm at month-2, 4 and 6

From: Predictors of delayed culture conversion among Ugandan patients

Month

Culture

Overall

Treatment Arm

 

CR

SR1

SR2

p-valueb

Converted, n/N, %

Converted, n/N, %

Converted, n/N,%

Converted, n/N, %

 

Month-2

LJ

51/91 (56.0)

17/32 (53.1)

14/27 (51.9)

20/32 (62.5)

0.697

MGIT

46/95 (48.4)

18/33 (54.6)

13/31 (41.9)

15/31 (48.4)

0.601

% difference

7.6

−1.5

10

14.1

 

p-valuea

0.0707

1.0000

0.1250

0.2891

 

Both LJ and MGIT

45/100 (45.0)

17/34 (50.0)

13/32 (40.6)

15/34 (44.1)

0.721

Month-4

LJ

88/89 (98.9)

31/31 (100.0)

28/29 (96.6)

29/29 (100.0)

0.652

MGIT

76/86 (88.4)

29/32 (90.6)

24/27 (88.9)

23/27 (85.2)

0.913

% difference

10.5

9.4

7.7

14.8

 

p-valuea

0.0391

0.5000

0.6250

0.2500

 

Both LJ and MGIT

82/94 (87.2)

31/34 (91.2)

25/30 (83.3)

26/30 (86.7)

0.685

Month-6

LJ

87/87 (100.0)

33/33 (100.0)

26/26 (100.0)

28/28 (100.0)

NA

MGIT

78/78 (100.0)

29/29 (100.0)

26/26 (100.0)

23/23 (100.0)

NA

% difference

0.0

0.0

0.0

0.0

 

p-valuea

1.0000

1.0000

1.0000

1.0000

 

Both LJ and MGIT

88/88 (100.0)

34/34 (100.0)

26/26 (100.0)

28/28 (100.0)

NA

  1. aExact McNemar p-value
  2. bFishers’ exact p-value
  3. Converted culture converted, CR control regimen (10 mg/kg rifampicin), SR1 study regimen1 (15 mg/kg rifampicin), SR2 study regimen2 (20 mg/kg rifampicin), LJ Löwenstein-Jensen, MGIT mycobacterium growth indicator tube